September 22, 2022
Video
There are 2 FDA-approved PSMA-PET imaging agents: Gallium 68 PSMA-11 (Ga 68 PSMA-11) and piflufolastat F 18.
September 20, 2022
Article
In this interview, William P. Parker, MD, highlights the development of PSMA-PET imaging in prostate cancer, FDA-approved PSMA-PET agents, and the next steps with this disruptive technique.
September 16, 2022
“PSMA-PET imaging is something that from a clinical practice perspective is rapidly changing and evolving the field of prostate cancer,” says William P. Parker, MD.
September 06, 2022
The target of 64Cu SAR-Bombesin is the Gastrin Releasing Peptide receptor, which is found on prostate tumors as well as several other tumors.
September 02, 2022
Experts weigh in on whether the combined technologies could be the future power couple of prostate cancer diagnosis.
July 28, 2022
The novel PET imaging agent 68GA-EMP-100 PET measures c-MET expression in renal cell carcinoma.
July 20, 2022
The PROPELLER trial is exploring the novel PSMA-PET imaging product 64Cu-SAR-bisPSMA in patients with treatment-naïve, histologically confirmed prostate cancer who are scheduled for radical prostatectomy
July 12, 2022
The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses
June 30, 2022
177Lu-PSMA-617 is FDA-approved for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer.
June 23, 2022
177Lu-PSMA-617 is approved by the FDA for previously treated patients with PSMA-positive metastatic castration-resistant prostate cancer.
